| Symbol | MTST |
|---|---|
| Name | METASTAT, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 02210 United States MA 27 Drydock Avenue 2ndFloor |
| Telephone | +1 (617) 531-6500 |
| Fax | — |
| — | |
| Website | http://www.metastat.com |
| Incorporation | US |
| Incorporated On | 2007 |
| Employees | — |
| Fiscal Year | 2/28 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | EisnerAmper LLP; |
| Audit Status | NOT AVAILABLE |
| Reporting Status | Dark: Alternative Reporting Standard |
| CIK | 0001404943 |
| Description | MetaStat is a precision medicine company dedicated to transforming the treatment of patients with aggressive cancer. Our mission is to evolve cancer treatment into a manageable disease through targeted therapies that arrest cancer cell dissemination and metastatic progression. Aggressive cancer that spreads or metastasizes to other parts of the body is responsible for approximately 90% of cancer-related deaths, yet there are no anti-metastatic drugs on the market. MetaStats drug discovery program is focused on developing novel drug candidates that target the Mena-dependent metastatic cascade. MetaStat is developing novel small molecule and peptide-based kinase inhibitors that target the MAPKAPK2 pathway responsible for activation of Mena. The companys Mena CDx companion diagnostic assay identifies patients with Mena-high tumors at risk for cancer metastasis and most likely to benefit from anti-Mena therapy. MetaStat is based in Boston, MA. Additional info from OTC: |